January 26, 2009
Richard E. Donovan was quoted in a Competition Law360 article titled "Pfizer, Wyeth Merger May Test Obama FTC's Mettle."
The article focused on the proposed merger between Pfizer Inc. and Wyeth Inc., two of the largest pharmaceutical companies in the United States. The article discussed how the Federal Trade Commission's management of this case "could provide solid insight into the Obama administration's approach on such industry-altering deals."
The article also examined the possible "overlaps between the products the companies currently have on the market, as well as the products in the research and development stages."
"'For example, Wyeth is strong in biotech, vaccines and consumer health products, while Pfizer is more focused on prescription drugs,' said Richard Donovan, co-chairman of the antitrust group at Kelley Drye & Warren LLP. 'But you have to get into the nitty gritty of it to see if there are any material overlaps.'"